Seminars in Oncology
Volume 31, Issue 4 , Pages 476-486, August 2004

Molecular biology of upper gastrointestinal malignancies

  • Jules Lin

      Affiliations

    • Corresponding Author InformationAddress reprint requests to David G. Beer, Department of Surgery, Section of General Thoracic Surgery, MSRB II B560, Box 0686, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • Section of General Thoracic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA
  • ,
  • David G. Beerm

      Affiliations

    • Section of General Thoracic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA

Abstract 

While cancers of the upper gastrointestinal tract are related by location, they have distinct clinical and molecular characteristics. This review will focus on the molecular biology of esophageal adenocarcinoma (EAC) of which alterations in p53, overexpression of cyclin D1, loss of p16, and aneuploidy have been best characterized. Key similarities and differences, when compared to esophageal squamous cell carcinoma (ESCC), gastric adenocarcinoma (GC), and adenocarcinoma of the gastric cardia (AGC), will also be highlighted. Currently, malignancies of the upper gastrointestinal tract are often diagnosed at an advanced stage and are generally associated with a poor patient prognosis. With an improved understanding of the molecular biology of these tumors, there is hope that new targets for diagnosis, chemoprevention, and therapy will be developed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by National Institutes of Health T32 Surgical Oncology Research Training Program CA009672-13 and National Cancer Institute Grant No. CA71606

PII: S0093-7754(04)00240-4

doi:10.1053/j.seminoncol.2004.04.019

Seminars in Oncology
Volume 31, Issue 4 , Pages 476-486, August 2004